AstraZeneca’s FluMist is a needle-free nasal spray with comparable effectiveness and acceptable safety relative to other flu vaccines, according to an Oct. 24 company news release. If approved, it would be eligible for patients 2 to 49 years old.
The FDA is expected to make a regulatory decision in the first quarter of 2024, and if approved, FluMist would be available for the 2024-25 flu season.
